← Back to Search

Other

BI 690517 mild hepatic impairment (Child-Pugh A) for Liver Disease

Phase 1
Waitlist Available
Research Sponsored by Boehringer Ingelheim
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Body mass index of 18.5 to 36.0 kg/m2 (inclusive)
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 4 days
Awards & highlights

Study Summary

This trial tests how mild & moderate liver disease affects drug safety, how it's absorbed & how well it's tolerated.

Eligible Conditions
  • Liver Disease
  • Healthy Subjects

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
Your body mass index (BMI) falls between 18.5 and 36.0 kg/m2.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 4 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 4 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)
Maximum measured concentration of the analyte in plasma (Cmax)
Secondary outcome measures
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz)

Trial Design

3Treatment groups
Experimental Treatment
Group I: BI 690517 normal hepatic functionExperimental Treatment1 Intervention
control group
Group II: BI 690517 moderate hepatic impairment (Child-Pugh B)Experimental Treatment1 Intervention
Group III: BI 690517 mild hepatic impairment (Child-Pugh A)Experimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
BI 690517
2017
Completed Phase 2
~1040

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

IQVIA global CROUNKNOWN
Boehringer IngelheimLead Sponsor
2,494 Previous Clinical Trials
10,916,844 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How much of a risk does BI 690517 mild hepatic impairment (Child-Pugh A) pose to individuals?

"With limited clinical evidence to support safety and efficacy, BI 690517 received a score of 1 for mild hepatic impairment (Child-Pugh A)."

Answered by AI

How numerous are the participants of this research endeavor?

"Indeed, the information publicly available from clinicaltrials.gov affirms that recruitment for this study is ongoing. It was originally advertised on February 21st 2023 and has been recently modified on February 27th 2023, with a goal of enrolling 32 subjects between 2 medical centers."

Answered by AI

Is there still capacity to enroll individuals in this experiment?

"The clinical trial is presently searching for participants, and its most recent iteration was posted on February 27th 2023. Furthermore, the original posting dates back to February 21st of that same year."

Answered by AI
~13 spots leftby Mar 2025